DBV Technologies SA
(FRA:DBV)
€
0.737
0.087 (13.38%)
Market Cap: 71.09 Mil
Enterprise Value: 34.75 Mil
PE Ratio: 0
PB Ratio: 1.32
GF Score: 36/100 DBV Technologies SA at Evercore ISI HealthCONx Conference Transcript
Dec 01, 2020 / 05:35PM GMT
Release Date Price:
€4.09
(-2.57%)
Liisa Ann Bayko
Evercore ISI Institutional Equities, Research Division - Research Analyst
Hi, Daniel. How are you?
Daniel TassÃ;DBV Technologies S.A.;CEO;Director
©,-&
I'm great, Liisa. How are you?
Liisa Ann Bayko
Evercore ISI Institutional Equities, Research Division - Research Analyst
I'm good. So I want to welcome Daniel Tassé, Chief Executive Officer of DBV Technologies. DBV is working in the area of peanut allergy. So a lot of enthusiasm there. Companies had its ups and downs, and I think they're working their way back up right now. So I think we're excited to get into the details. But maybe first, just to set the stage, Daniel, you can tell us a little bit more about DBV.
Daniel TassÃ;DBV Technologies S.A.;CEO;Director
©,-&
Yes. DBV is a company that is exploring the fact that the human skin is actually a pretty powerful immune organ, something that is not always well understood,
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot